Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — FY2021 Earnings Presentation
18 slides from Elixinol Wellness's earnings presentation, Feb 25, 2022
Slide 1: FY21 Results Presentation
ASX:EXL FY21 Results Presentation February 2022 1
Slide 2: Disclaimer
Disclaimer This presentation contains summary information about Elixinol Wellness Limited (Elixinol Wellness) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with Elixinol Wellness’ other periodic and c
Slide 3: Table of Contents
Table of Contents Vision & Purpose Executive Summary Operational Highlights Group Financial Highlights FY21 Financial Summary Business Unit Performance Digital First Strategy Progress FY21 Cash Flow FY21 Financial Position Outlook & Strategy Hemp Foods & CBD Outlook Global Strategy & Initiatives New
Slide 4: To create a healthier everyday life through the power of hemp and plant-based products
Elixinol CBD Brand (Digestible & Topical Products) VISION To create a healthier everyday life through the power of hemp and plant-based products AMBITION Building a global, hemp-centric wellness consumer products company PURPOSE Hemp Foods Australia (Foods, Supplements & Skincare) Changing lives nat
Slide 5: FY21 Executive Summary
Elixinol Americas continued its transformation agenda towards a capital FY21 Executive Summary light and e-commerce led branded wellness products business. A more focused channel and product strategy delivered a 14 pts Gross Margin improvement to 71% (FY20: 57%) whilst operating expenses were Contin
Slide 6: Operational Highlights
Operational Large scale business transformation drives $11.3m Investment focus on AU and US markets with strongest competitive position simplifies Highlights OPEX savings with further optimisation initiatives available. our business model and enables Group to compete more effectively. Group wide tra
Slide 7: Group Financial Highlights
Group Financial Highlights Elixinol Wellness is on a consistent EBITDA improvement trajectory having delivered its best EBITDA performance in recent periods and continues well capitalized with a strong cash position. FY21 Revenues: $9.3m (-38% vs PY) A$’000, FY21 1,011 988 914 857 667 752 749 696 71
Slide 8: FY21 Financial Summary
FY21 Financial Summary Focus on higher margin branded products, e-commerce and tight cost controls drives significant profit improvement. A$’m FY21 FY20 Revenue 9.3 15.0 Cost of goods sold (4.4) (8.3) Gross profit 4.9 6.7 GP% 52% 45% Operating expenses (18.8) (29.1) Non-operating (expenses)/income 2
Slide 9: FY21 Business Unit Performance
FY21 Business Unit Performance EBITDA improvement across all business units. A$’m Americas Europe Australia Corporate FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 Revenue 4.8 8.5 0.5 2.3 4.1 4.2 Gross profit 3.4 4.9 0.1 0.8 1.4 1.1 GP% 71% 57% 25% 32% 34% 27% Operating expenses (10.6) (17.6) (2.5) (5.2)
Slide 10: Digital Strategy Drives Growth and Profitability
Digital Strategy Drives Growth and Profitability 39% of revenue was derived from e-commerce in FY21 (FY20: 33%). Continued efforts to move towards a digital growth business have yielded strong progress, with more upside ahead as the business focuses on attracting new consumers and improving user exp
Slide 11: FY21 Cash Flow
FY21 Cash Flow • Simplified operating model has driven significant cost savings: 38% reduction in cash used in operations. • 38% reduction in cash used operating activities vs FY20 • 39% reduction in normalised operating cash outflows vs FY20 • Based on Q4 FY21, approximately 5 quarters of funding (
Slide 12: FY21 Financial Position
FY21 Financial Position Well funded with $12.6m cash and virtually no debt. A$’m 31 Dec 2021 31 Dec 2020 Current assets Cash and cash equivalents 12.6 27.7 Trade & other receivables 3.0 1.2 Inventories 2.2 4.7 Other 1.8 1.8 Total current assets 19.6 35.4 Non-current assets Property, plant and equipm
Slide 13: Outlook & Strategy
Outlook & Strategy 13
Slide 14: Outlook: Hemp food and CBD products an answer to the growing trend for plant-based nutrition
Outlook: Hemp food and CBD products an answer to the growing trend for plant-based nutrition and nutraceuticals Hemp food in Australia CBD in U.S.A. The rise in dietary trends such as vegan / vegetarian and flexitarian has seen Sales are expected to reach $12.0 billion by 2026, driven by consumers t
Slide 15: Global Strategy & Initiatives
Global Strategy & Initiatives VISION: To create a healthier everyday life through the power of hemp & plant-based products REGIONAL PRIORITIES: As we re-build profitability, we will focus our investments on our most established markets in the US and Australia where we have a strong competitive posit
Slide 16: New Product Development Initiatives
New Product Development Initiatives FY21 investment in building a R&D and innovation capability has delivered a wide reaching new product launch pipeline that will see new product throughout H1 FY22. LAUNCHED COMING • Sleep Liposomes • Functional gummies Elixinol will expand CBD offering with new •
Slide 17: Summary
Well positioned in global consumer wellness trend for natural and plant-based food and nutraceuticals Business transformation Improved outlook has improved due to a better economic and will further strengthen environment and end of COVID- fundamentals 19 restrictions Summary New product development
Slide 18: Thank you
Thank you @ ElixinolWellness Natural wellness for people and the planet